Showing results (121-130 of 225) with videos related to

Sort By:
Pageof 23
Cancers|December 7, 2019
Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus DocumentAlberto Lapini, Orazio Caffo, Giovanni Pappagallo, et al.
Expert Review of Molecular Diagnostics|January 29, 2020
Biomarkers of response to advanced prostate cancer therapyRoberto Iacovelli, Chiara Ciccarese, Giovanni Schinzari, et al.
International Journal of Cancer|February 24, 2015
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumabValeria Musella, Filippo Pietrantonio, Eleonora Di Buduo, et al.
Urologic Oncology|October 11, 2018
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinomaDavide Bimbatti, Chiara Ciccarese, Emanuela Fantinel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 13, 2015
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisFilippo Pietrantonio, Fausto Petrelli, Andrea Coinu, et al.
Tumori|October 30, 2025
A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 StudyChiara Ciccarese, Daniela Arduini, Francesca Primi, et al.
European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.
Targeted Oncology|April 17, 2025
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsGiada Pinterpe, Fortuna Migliaccio, Chiara Ciccarese, et al.
Plos One|April 3, 2014
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusFilippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, et al.
Critical Reviews in Oncology/Hematology|August 12, 2019
Toward a genome-based treatment landscape for renal cell carcinomaFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Pageof 23